Study out of Quebec finds bone mineral density testing for patients with prostate cancer undergoing ADT therapy are not meeting guideline recommendations.
From the report (linked below):
". . . In particular, bone metabolism is highly affected and the loss of bone mineral density (BMD) is accelerated due to the deficiency of estrogen that accompanies androgen suppression.17 Consequently, ADT increases the risk of osteoporosis and fractures, as demonstrated by numerous studies.18–20 The impact of fractures incurs a large burden at the patient level (diminishes quality of life and increases mortality) and the societal level (cost of healthcare services associated with management).21–24"
Article is here:
nccn.org/about/news/newsinf...
And full published report is here:
jnccn.org/view/journals/jnc...
Those of you on ADT should read both the article and report and, if not currently being tested for bone mineral density, discuss having regular BMD testing with your MO and adding an appropriate adjuvant treatment when needed.
Stay Safe & Well, K9